Therapeutic potential of matrix metalloproteinase inhibitors in atherosclerosis

Bibliography

• NAGASE H, WOESSNER JF: Matrix metalloproteinases. J. Biol. Chem. (1999) 274:21491-21494. A brief but excellent review of the MMP family.
   Google Scholar
• NAGASE H: Activation mechanisms of matrix metallo-proteinases. Biol. Chem. (1997) 378:151–160.
   PubMed Web of Science ®Google Scholar
• MATRISIAN LM: Matrix metalloproteinase gene expres-sion. In: Inhibition of Matrix Metalloproteinases: Therapeutic Potential. Greenwald RA, Golub LM (Eds.), NY Acad. Sci., New York, USA (1994):42–50.
   Google Scholar
• MATRISIAN LM: Metalloproteinases and their inhibi-tors in matrix remodeling. Trends Genetics (1990) 6:121–125.
   PubMed Web of Science ®Google Scholar
• PEI D: CA-MMP: A matrix metalloproteinase with anovel cysteine array, but without the classic cysteine switch. FEBS Lett. (1999) 457(2):262–270.
   PubMed Web of Science ®Google Scholar
• SHOFUDA K, YASUMITSU H, NISHIHASHI A, MIKI K,MIYAZAKI K: Expression of three membrane-type matrix metalloproteinases (MT-MMPs) in rat vascular smooth muscle cells and characterization of MT3-MMPs with and without transmembrane domain. J. Biol. Chem. (1997) 272(15):9749–9754.
   PubMed Web of Science ®Google Scholar
• PEI D: Identification and characterization of the fifthmembrane-type matrix metalloproteinase MT5-MMP. J. Biol. Chem. (1999) 274:8925–8932.
   PubMed Web of Science ®Google Scholar
• •An interesting paper which introduces the fifth member of the MT-MMP class and highlights the potential involvement of soluble MT-MMPs in extracellular matrix remodelling.
   Google Scholar
• LACRAZ S, ISLER P, E. V, WELGUS HG, DAYER J-M: Directcontact between T-lymphocytes and monocytes is a major pathway for induction of metalloproteinase expression. J. Biol. Chem. (1994) 269:22027–22033.
   Google Scholar
• MALIK N, GREENFIELD BW, WAHL AF, KIENER PA: Activa-tion of human monocytes through CD40 induces matrix metalloproteinases. J. Immunol. (1996) 156:3952–3960.
   PubMed Web of Science ®Google Scholar
• MACH F, SCHOBECK U, SUKHOVA GK et al: FunctionalCD40 ligand is expressed on human vascular endothe-lial cells, smooth muscle cells and macrophages: Implications for CD40-CD40 ligand signaling in atherosclerosis. Proc. Natl. Acad. Sci. USA (1997) 94:1931–1936.
   PubMed Web of Science ®Google Scholar
• SCHONBECK U, MACH F, SUKHOVA GK et al.: Regulationof matrix metalloproteinase expression in human vascular smooth muscle cells by lymphocytes. A role for CD40 signaling in plaque rupture? Circ. Res. (1997) 81:448–454.
   Google Scholar
• •This study illustrated for the first time that cell-cell contact between activated T-lymphocytes and vascular SMC via CD40 ligation induces the expression of MMP-1, MMP-3 and MMP-9, suggesting that cell-cell contact through CD40 may play a pivotal role in MMP induction in atherosclerosis.
   Google Scholar
• PEI D, WEISS SJ: Furin-dependent intracellular activation of the human stromelysin-3 zymogen. Nature (1995) 375:244–247.
   PubMed Web of Science ®Google Scholar
• WILLENBROCK F, MURPHY G: Structure-function relationships in the tissue inhibitors of metalloprote-inases. Am. J. Respir. Grit. Care Med. (1994) 150:S165–S170.
   PubMed Web of Science ®Google Scholar
• GOLDBERG GI, MARMER BL, GRANT GA, EISEN AZ, WILHELM S, HE C: Human 72-kilodalton Type IV collagenase forms a complex with a tissue inhibitor of metalloproteases designated TIMP-2. Proc. Natl. Acad. Sci. USA (1989) 86:8207–8211.
   PubMed Web of Science ®Google Scholar
• STETLER-STEVENSON WG, KRUTZCH HC, LIOTTA LA: Tissue inhibitor of metalloproteinase (TIMP-2). A new member of the metalloproteinase inhibitor family. J. Biol. Chem. (1989) 264(29):17374–17378.
   Google Scholar
• BAKER AH, ZALTSMAN AB, GEORGE SJ, NEWBY AC: Divergent effects of tissue inhibitor of metalloproteinase-1, -2, or -3 overexpression on rat vascular smooth muscle cell invasion, proliferation and death in vitro. TIMP-3 promotes apoptosis. J. Clin. Invest. (1998) 101:1478–1487.
   PubMed Web of Science ®Google Scholar
• •This paper shows that TIMP-3 is involved in apoptosis in vascular SMC.
   Google Scholar
• HAYAKAWA T, YAMASHITA K, TANZAWA K, UCHIJIMA E, IWATA K: Growth-promoting activity of tissue inhibitor of metalloproteinases-1 (TIMP-1) for a wide range of cells. A possible new growth factor in serum. FEBS Lett. (1992) 298:29–32.
   Google Scholar
• •Shows that TIMP-1, TIMP-2 and TIMP-3 have growth factor properties in some cell types.
   Google Scholar
• STETLER-STEVENSON WG, BERSCH N, GOLDE DW: Tissue inhibitor of metalloproteinase-2 (TIMP-2) has erythroid-potentiating activity. FEBS Lett. (1992) 296:231–234.
   PubMed Web of Science ®Google Scholar
• •See reference 17 for annotation.
   Google Scholar
• YAMASHITA K, SUZUKI M, IWATA H et al: Tyrosine phosphorylation is crucial for growth signaling by tissue inhibitors of metalloproteinases (TIMP-1 and TIMP-2). FEBS Lett. (1996) 396 (1) 103–107.
   PubMed Web of Science ®Google Scholar
• •See reference 17 for annotation.
   Google Scholar
• YANG T-T, HAWKES SP: Role of the 21-kDa protein TIMP-3 in oncogenic transformation of cultured chicken embryo fibroblasts. Proc. Natl. Acad. Sci. USA (1992) 89:10676–10680.
   PubMed Web of Science ®Google Scholar
• •See reference 17 for annotation.
   Google Scholar
• LECO KJ, KHOKHA R, PAVLOFF N, HAWKES SP, EDWARDS DR: Tissue inhibitor of metalloproteinases-3 (TIMP-3) is an extracellular matrix-associated protein with a distinctive pattern of expression in mouse cells and tissues. J. Biol. Chem. (1994) 269:9352–9360.
   PubMed Web of Science ®Google Scholar
• •See reference 17 for annotation.
   Google Scholar
• STRICKLIN GP, LI L, NANNEY NB: Localization of mRNAsrepresenting interstitial collagenase, 72-kDa gelati-nase and TIMP in healing porcine burn wounds. J. Invest. Dermatol. (1994) 103:352–358.
   PubMed Web of Science ®Google Scholar
• STRONGIN AY, COLLIER I, BANNIKOV G, MARMER BL,GRANT GA, GOLDBERG GI: Mechanism of cell-surface activation of 72 kDa Type IV collagenase - isolation of the activated form of membrane metalloprotease. J. Biol. Chem. (1995) 270(105331–5339.
   Web of Science ®Google Scholar
• NAGASE H, ITOH Y, BINNER S: Interaction of a2-macroglobulin with matrix metalloproteinases and its use for identification of their active forms. In: Inhibition of Matrix Metalloproteinases: Therapeutic Potential. Greenwald RA, Golub LM (Eds.), NY Acad Sci, New York, USA (1994):294–302.
   Google Scholar
• TAKAHASHI C, SHENG Z, HORAN TP et al: Regulation of matrix metalloproteinase-9 and inhibition of tumor invasion by the membrane-anchored glycoprotein RECK. Proc. Natl. Acad. Sci. USA (1998) 95:13221–13226.
   PubMed Web of Science ®Google Scholar
• NEWBY AC, ZALTSMAN AB: Fibrous cap formation or destruction - the critical importance of vascular smooth muscle cell proliferation, migration and matrix formation. Cardiovasc. Res. (1999) 41:345–360.
   PubMed Web of Science ®Google Scholar
• SHANAHAN CM, WEISSBERG PL, METCALFE JC: Isolation of gene markers of differentiated and proliferating vascular smooth muscle cells. Circ. Res. (1993) 73(1):193–204.
   PubMed Web of Science ®Google Scholar
• THYBERG J: Phenotypic modulation of smooth muscle cells during formation of neointimal thickenings following vascular injury. Histol Histopathol (1998) 13:871–891.
   PubMed Web of Science ®Google Scholar
• LEVI E, FRIDMAN R, MIAO H-Q, YAYON A, VLODAVSKY I: Matrix-metalloproteinase 2 releases active soluble ectodomain of fibroblast growth factor receptor 1. Proc. Natl. Acad. Sci. USA (1996) 93:7069–7074.
   PubMed Web of Science ®Google Scholar
• STREULI C: Extracellular matrix remodelling and cellular differentiation. Curr. Opin. Cell Biol. (1999) 11:634–640.
   PubMed Web of Science ®Google Scholar
• ••This excellent review examines the role of extracellularmatrix degradation on cell behaviour.
   Google Scholar
• CORNELIUS LA, NEHRING LC, HARDING E et al.: Matrix metalloproteinases generate antiostatin: Effects on neovascularization. j Immunol (1998) 161:6845–6852.
   PubMed Web of Science ®Google Scholar
• GERRITY RG: The role of the monocyte in athero-genesis. II. migration of foam cells from atheroscle-rotic lesions. Am. J. Pathol. (1981) 103:191–200.
   Google Scholar
• ROMANIC AM, MADRI JA: The induction of 72-kD gelati-nase in T cells upon adhesion to endothelial cells is VCAM-1 dependent. J. Cell Biol. (1994) 125 (5) 1165–1178.
   PubMed Web of Science ®Google Scholar
• MADRI JA, GRAESSER D, HAAS T: The roles of adhesionmolecules and proteinases in lymphocyte transendo-thelial migration. Biochem. Cell Biol. (1996) 74:749–757.
   PubMed Web of Science ®Google Scholar
• WESLEY RB, MENG X, GODIN D, GALIS ZS: Extracellularmatrix modulates macrophage functions character-istic to atheroma. Collagen Type I enhances acquistion of resident macrophage traits by human peripheral blood monocytes in vitro. Arterioscler. Thromb. Vasc. Biol. (1998) 18:432–440.
   Google Scholar
• •In this study it is demonstrated that the interaction of monocytes with extracellular matrix, particularly collagen Type I, induces MMP-9 expression.
   Google Scholar
• KHAN KMF, FALCONE DJ: Role of laminin in matrixinduction of macrophage urokinase-type plasminogen activitator and 92-kDa metalloprote-inase expression. J. Biol. Chem. (1997) 272:8270–8275.
   PubMed Web of Science ®Google Scholar
• CAMPBELL JH, KALEVITCH SG, RENNICK RE, CAMPBELLGR: Extracellular matrix-smooth muscle phenotype modulation by macrophages. Ann. NY Acad. Sci. (1990) 598:159–166.
   PubMed Web of Science ®Google Scholar
• CAMPBELL GR, CAMPBELL JH: The phenotypes of smooth muscle expressed in human atheroma. Ann. NY Acad. Sci. (1990) 598:143–158.
   PubMed Web of Science ®Google Scholar
• BENDECK MP, ZEMPO N, CLOWES AW, GALARDY RE, REIDY MA: Smooth muscle cell migration and matrix metalloproteinase expression after arterial injury in the rat. Circ. Res. (1994) 75:539–545.
   PubMed Web of Science ®Google Scholar
• ZEMPO N, KENAGY RD, AU T et al.: Matrix metalloprote-inases of vascular wall cells are increased in balloon-injured rat carotid. J.Vasc. Surg. (1994) 20:209–217.
   PubMed Web of Science ®Google Scholar
• WEBB KE, HENNEY AM, ANGLIN S, HUMPHRIES SE, MCEWAN JR: Expression of matrix metalloproteinases and their inhibitor TIMP-1 in the rat carotid artery after balloon injury. Arterioscler. Thromb. Vasc. Biol. (1997) 17(9):1837–1844.
   PubMed Web of Science ®Google Scholar
• JENKINS GM, CROW MT, BILATO C et al.: Increasedexpression of membrane-type matrix metalloprote-inase and preferential localization of matrix metalloproteinase-2 to the neointima of balloon-injured rat carotid arteries. Circulation (1998) 97:82–90.
   PubMed Web of Science ®Google Scholar
• LUNEN HR, VAN HOEF B, LUPU F et al.: Function of theplasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targetted inactivation of fibrinolytic system genes. Arterioscler. Thromb. Vasc. Biol. (1998) 18:1035–1045.
   PubMed Web of Science ®Google Scholar
• LUNEN HR, SOLOWAY P, COLLEN D: Tissue inhibitor of matrix metalloproteinase-1 impairs arterial neointima formation after vascular injury in mice. Circ. Res. (1999) 85:1186–1191.
   PubMed Web of Science ®Google Scholar
• ••This recent study clearly demonstrates that MMPs play a rolein SMC migration and therefore intimal thickening in mice after electric injury.
   Google Scholar
• MASON DP, KENAGY RD, HASENSTAB D et al.: Matrix metalloproteinase-9 overexpression enhances vascular smooth muscle cell migration and alters remodelling in the injured rat carotid artery. Circ. Res. (1999) 85:1179–1185.
   PubMed Web of Science ®Google Scholar
• ••This interesting study suggests that in addition to beinginvolved in SMC migration after injury, MMP-9 may also play a beneficial role in vessel remodelling.
   Google Scholar
• FOROUGH R, HASENSTAB D, ZEMPO N, LANGLEY K, DECLERCK Y, CLOWES A: Induction of tissue inhibitor of metalloproteinase-2 in injured rat artery. In: Inhibition of Matrix Metalloproteinases: Therapeutic Potential. Greenwald RA, Golub LM (Ed.), NY Acad. Sci., New York, USA (1994):384–388.
   Google Scholar
• WANG H, KEISER JA: Expression of membrane-typematrix metalloproteinase in rabbit neointimal tissue and its correlation with matrix-metalloproteinase-2 activation. J. Vasc. Res. (1998) 35:45–54.
   PubMed Web of Science ®Google Scholar
• DOLLERY CM, MCEWAN JR, WANG M, SANG QA, LIU YE, SHI E: TIMP-4 is regulated by vascular injury in rats. Circ. Res. (1999) 84:498–504.
   PubMed Web of Science ®Google Scholar
• •This study is the first demonstration of TIMP-4 expression in rat vessels after injury.
   Google Scholar
• BARGER AC, BEEUWKES R, LAINEY LL, SILVERMAN KV:Hypothesis: vasa vasorum and neovascularisation of human coronary arteries. Possible role in the pathophysiology of atheroscelerosis. N Engl. J. Med. (1984) 310:175.
   PubMed Web of Science ®Google Scholar
• ZHANG Y, CLIFF WJ, SCHOEFL GI, HIGGINS G: Immuno-histochemical study of intimal microvessels in coronary atherosclerosis. Am. J. PathoL (1993) 143(0:164–172.
   PubMed Web of Science ®Google Scholar
• KUMAMOTO M, NAKASHIMA Y, SUEISHI K: Intimal neovascularization in human coronary atheroscle-rosis: Its origin and pathophysiological significance. Hum. Pathol (1995) 26(4)450–456.
   Google Scholar
• HERRON GS, BANDA MJ, CLARK EJ, GAVRILOVIC J, WERBZ: Secretion of metalloproteinases by stimulated capillary endothelial cells. II Expression of collage-nase and stromelysin activities is regulated by endoge-nous inhibitors. J. Biol. Chem. (1986) 261:2814–2818.
   Google Scholar
• SCHNAPER HW, GRANT DS, STETLER-STEVENSON WG etal: Type IV collagenases(s) and TIMPs modulate endothelial cell morphogenesis in vitro. J. Cell. Physiol. (1993) 156:235–246.
   PubMed Web of Science ®Google Scholar
• JOHNSON MD, KIM H-RC, CHESLER L, TSAO-WU G, BOUCK N, POLVERINI PJ: Inhibition of angiogenesis by tissue inhibitor of metalloproteinase. J. Cell. Physiol. (1994) 160:194–202.
   PubMed Web of Science ®Google Scholar
• MCMILLAN WD, PATTERSON BK, KEEN RR, SHIVELY VP,CIPOLLONE M, PEARCE WH: In situ localisation and quantification of mRNA for 92-kD Type IV collagenase and its inhibitor in aneurysmal, occlusive and normal aorta. Arterioscler. Thromb. Vasc. Biol. (1 9 9 5) 15:1139-1144.
   Google Scholar
• SUNDERKOTTER C, STEINBRINK K, GOEBELER M, BHARDWAJ R, SORG C: Macrophages and angiogenesis. Leukoc. Biol. (1994) 55:410–422.
   PubMed Web of Science ®Google Scholar
• CHANDLER S, COSSINS J, LURY J, WELLS G: Macrophagemetalloelastase degrades matrix and myelin proteins and processes a tumour necrosis factor-a fusion protein. Biochem. Biophys. Res. Comm. (1 99 6) 228:421–429.
   Google Scholar
• FOWLKES JL, ENGHILD JJ, SUZUKI K, NAGASE H: Matrixmetalloproteinases degrade insulin-like growth factor-binding protein-3 in dermal fibroblast cultures. J. Biol. Chem. (1994) 269(40:25742–25746.
   PubMed Web of Science ®Google Scholar
• LUNEN HR, UGWU F, BINI A, COLLEN D: Generation ofan angiostain-like fragment from plasminogen by stromelysin-1 (MMP-3). Biochemistry (1 9 9 8) 37:4699-4702.
   Google Scholar
• PATTERSON BC, SANG QXA: Angiostatin-converting enzyme activities of human matrilysin (MMP-7) and gelatinase B Type IV collagenase (MMP-9). J Biol. Chem. (1997) 272(46):28823–28825.
   PubMed Web of Science ®Google Scholar
• DONG Z, KUMAR R, YANG X, FIDLER IJ: Macrophage-derived metalloelastase is responsible for the genera-tion of angiostatin in Lewis lung carcinoma. Cell (1997) 88:801–810.
   PubMed Web of Science ®Google Scholar
• STARY HC, CHANDLER AB, DINSMORE RE et al: A defini-tion of advanced types of atherosclerotic lesions and a histological classification of atherosclerosis: A report from the Committee on Vascular Lesions of the Council on Arteriosclerosis, American Heart Associa-tion. Circulation (1995) 92(5):1355–1374.
   PubMed Web of Science ®Google Scholar
• DAVIES MJ, THOMAS AC: Plaque fissuring - the cause of acute myocardial infarction, sudden ischaemic death and crescendo angina. Br. Heart J. (1985) 53:363–373.
   PubMedGoogle Scholar
• FALK E. Why do plaques rupture? Circulation (1992) 86:11130–42.
   Web of Science ®Google Scholar
• SHAH PK: Pathophysiology of plaque rupture and theconcept of plaque stabilization. Cardiol. Clin. (1996) 14:17–29.
   PubMedGoogle Scholar
• GALIS ZS, SUKHOVA GK, KRANZHOFER R, CLARK S, LIBBY P: Macrophage foam cells from experimental atheroma constitutively produce matrix-degrading proteinases. Proc. Natl. Acad. Sci. USA (1995) 92:402–406.
   PubMed Web of Science ®Google Scholar
• SHAH PK, FALK E, BADIMON JJ et al.: Human monocyte-derived macrophages induce collagen breakdown in fibrous caps of atherosclerotic plaques: Potential role of matrix-degrading metalloproteinases and implica-tions for plaque rupture. Circulation (1 9 9 5) 92 (6) :1565-1569.
   Google Scholar
• GALIS ZS, SUKHOVA GK, LARK MW, LIBBY P: Increasedexpression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J. Clin. Invest. (1994) 94:2493–2503.
   PubMed Web of Science ®Google Scholar
• NIKKARI ST, GEARY RL, HATSUKAMI T et al.: Expressionof collagen, interstitial collagenase and tissue inhibitor of metalloproteinase-1 in restenosis after carotid endarterectomy. Am. J. Pathol. (1996) 148:777–783.
   PubMed Web of Science ®Google Scholar
• HENNEY AM, WAKELEY PR, DAVIES MJ et al: Localizationof stromelysin gene expression in atherosclerotic plaques by in situ hybridization. Proc. Natl. Acad. Sci. USA (1991) 88:8154–8158.
   PubMed Web of Science ®Google Scholar
• BROWN DL, HIBBS MS, KEARNEY M, LOUSHIN C, ISNER JM: Identification of 92-kD gelatinase in human coronary atherosclerotic lesions. Association of active enzyme synthesis with unstable angina. Circulation (1995) 91:2125–2131.
   Google Scholar
• HALPERT I, SIRES UI, ROBY JD et al.: Matrilysin is expressed by lipid-laden macrophages at sites of potential rupture in atherosclerotic lesions and localizes to areas of versican deposition, a proteo-glycan substrate for the enzyme. Proc. Natl. Acad. Sci. USA (1996) 93:9748–9753.
   PubMed Web of Science ®Google Scholar
• SCHONBECK U, MACH F, SUKHOVA GK et al.: Expres-sion of stromelysin-3 in atherosclerotic lesions: Regulation via CD4O-CD40 ligand signaling in vitro and in vivo. J. Exp. Med. (1999) 189(5):843–853.
   PubMed Web of Science ®Google Scholar
• SUKHOVA GK, SCHONBECK U, RABKIN E et al.: Evidence for increased collagenolysis by interstitial collagenases-1 and-3 in vulnerable human atheroma-tous plaques. Circulation (1999) 99:2503–2509.
   PubMed Web of Science ®Google Scholar
• RAJAVASHISTH TB, XU XP, JOVINGE S et al.: Membrane Type 1 matrix metalloproteinase expression in human atherosclerotic plaques - Evidence for activa-tion by proinflammatory mediators. Circulation (1999) 99:3103–3109.
   PubMed Web of Science ®Google Scholar
• SHAPIRO SD, CAMPBELL EJ, SENIOR RM, WELGUS HG: Proteinases secreted by human mononuclear phagocytes. J. Rheumatol. (1991) 18:95–98.
   PubMed Web of Science ®Google Scholar
• MAST AE, ENGHILD JJ, NAGASE H et al.: Kinetics and physiologic relevance of the inactivation of alphal-proteinase inhibitor, alphal-antichymotrypsin and antithrombin III by matrix metalloproteinases-1 (tissue collagenase, -2 (72 kDa gelatainase/type IV collagenase) and -3 (stromelysin). J. Biol. Chem. (1991) 266(24):15810–15816.
   PubMed Web of Science ®Google Scholar
• DESROCHERS PE, JEFFREY JJ, WEISS SJ: Interstitialcollagenase (matrix metalloproteinase-1) expresses serpinase activity. J. Clin Invest. (1991) 87 (6) :2258–2265.
   PubMed Web of Science ®Google Scholar
• DESROCHERS PE, MOOKHITAR K, VAN WART HE, HASTY KA, WEISS SJ: Proteolytic inactivation of alpha 1-proteinase inhibitor and alphal-antichymotrypsin by oxidatively activated human neutrophil metalloprote-inases. j Biol Chem. 267 (7) :5005-5012.
   Google Scholar
• PEI D, MAJMUDAR G, WEISS SJ: Hydrolytic inactivation of a breast carcinoma cell-derived serpin by human stromelysin-3. J. Biol. Chem. (1994) 269 (41) 25849–25855.
   PubMed Web of Science ®Google Scholar
• LEE RT, SCHOEN FJ, LOREE HM, LARK MW, LIBBY P: Circumferential stress and matrix metalloproteinase 1 in human coronary atherosclerosis - Implications for plaque rupture. Arterioscler. Thromb. Vasc. Biol. (1996) 16:1070–1073.
   PubMed Web of Science ®Google Scholar
• GALIS ZS, MUSZYNSKI M, SUKHOVA GK et al.: Cytokine-stimulated human vascular smooth muscle synthesize a complement of enzymes required for extracellular matrix digestion. Circ. Res. (1994) 75:181–189.
   PubMed Web of Science ®Google Scholar
• KENAGY RD, NIKKARI ST, WELGUS HG, CLOWES AW: Heparin inhibits the induction of three matrix metalloproteinases (stomelysin, 92-kD gelatinase and collagenase) in primate arterial smooth muscle cells. J. Clin. Invest. (1994) 93:1987–1993.
   PubMed Web of Science ®Google Scholar
• FABUNMI RP, BAKER AH, MURRAY EJ, BOOTH RFG, NEWBY AC: Divergent regulation by growth factors and cytokines of 95 kDa and 72 kDa gelatinases and tissue inhibitors of metalloproteinases-1,-2 and -3 in rabbit aortic smooth muscle cells. Biochem. J. (1996)315:335–342.
   PubMed Web of Science ®Google Scholar
• FABUNMI RP, SUKHOVA GK, SUGIYAMA S, LIBBY P: Expression of tissue inhibitor of metalloproteinases-3 in human atheroma and regulation in lesion-associated cells. A potential protective mechanism in plaque stability. Circ. Res. (1998) 83:270–278.
   Google Scholar
• GALIS ZS, SUKHOVA GK, LIBBY P: Microscopic localiza-tion of active proteases by in situ zymography: Detection of matrix metalloproteinase activity in vascular tissue. FASEB J (1995) 9 (10) :974–980.
   PubMed Web of Science ®Google Scholar
• •Elegantly shows that the balance of the MMP:TIMP ratio in human and rabbit atherosclerotic plaques favours matrix degradation using in situ zymography.
   Google Scholar
• JOHNSON JL, JACKSON CL, ANGELINI GD, GEORGE SJ: Activation of matrix-degrading metalloproteinases by mast cell proteases in atherosclerotic plaques. Arterio-scler. Thromb. Vasc. Biol. (1998) 18:1707–1715.
   PubMed Web of Science ®Google Scholar
• •See reference 86 for annotation.
   Google Scholar
• ZALTSMAN AB, GEORGE SJ, NEWBY AC: Increased secretion of tissue inhibitors of metalloproteinases-1 and -2 from the aortas of cholesterol fed rabbits partially counterbalances increased metalloprote-inase activity. Arterioscler. Thromb. Vasc. Biol. (1999) 19:1700–1707.
   PubMed Web of Science ®Google Scholar
• •See reference 86 for annotation.
   Google Scholar
• MOREAU M, BROCHERIOU I, PETIT L, NINIO E, CHAPMANJ, ROUIS M: Interleukin-8 mediates downregulation of tissue inhibitor of metalloproteinase-1 expression in cholesterol-loaded human macrophages. Relevance to stability of atherosclerotic plaque. Circulation (1999) 99:420–426.
   Google Scholar
• LENDON CL, DAVIES MJ, BORN GVR, RICHARDSON PD:Atherosclerotic plaque caps are locally weakened when macrophage density is increased. Atherosclerosis (1991) 87:87–90.
   PubMed Web of Science ®Google Scholar
• KOCKX MM, DEMEYER GRY, MUHRING J, JACOB W, BULTH, HERMAN AG: Apoptosis and related proteins in different stages of human atherosclerotic plaques. Circulation (1998) 97(23) :2307–2315.
   PubMed Web of Science ®Google Scholar
• KOCKX MM: Apoptosis in the atherosclerositc plaque.Quantitative and qualitative aspects. Arterioscler. Thromb. Vasc. Biol. (1998) 18:1519–1522.
   PubMed Web of Science ®Google Scholar
• LEE E, GRODZINSKY AJ, LIBBY P, CLINTON SK, LARK MW,LEE RT: Human vascular smooth muscle cell-monocyte interactions and metalloproteinase secretion in culture. Arterioscler. Thromb. Vasc. Biol. (1995) 15:2284–2289.
   PubMed Web of Science ®Google Scholar
• RAJAVASHISTH TB, LIAO JK, GALIS ZS et al.: Inflamma-tory cytokines and oxidized low density lipoproteins increase endothelial cell expression of membrane Type 1-matrix metalloproteinase. J. Biol. Chem. (1999) 274(17):11924–11929.
   PubMed Web of Science ®Google Scholar
• SHAPIRO SD, CAMPBELL EJ, KOBAYASHI DK, WELGUSHG: Immune modulation of metalloproteinase production in human macrophages. Selective pretranslational suppression of interstitial collage-nase and stromelysin biosynthesis by interferon-y. J. Clin. Invest. (1990) 86:1204–1210.
   Google Scholar
• XIE B, DONG Z, FIDLER IJ: Regulatory mechanisms forthe expression of Type IV collagenases/gelatinases in murine macrophages. J. Immunol (1994) 152:3637–3644.
   PubMed Web of Science ®Google Scholar
• LACRAZ S, NICOD LP, CHICHEPORTICHE R, WELGUS HG,DAYER JM: IL-10 inhibits metalloproteinase and stimulates TIMP-1 production in human mononuclear phagocytes. J. Clin. Invest. (1995) 96(5):2304–2310.
   PubMed Web of Science ®Google Scholar
• SASAGURI T, ARIMA N, TANIMOTO A, SHIMAJIRI S,HAMADA T, SASAGURI Y: A role for interleukin 4 in production of matrix metalloproteinase 1 by human aortic smooth muscle cells. Atherosclerosis (1998) 138:247–253.
   PubMed Web of Science ®Google Scholar
• SATOH T, SUGAMA K, MATSUO A et al: Histamine as anactivator of cell growth and extracellular matrix reconstruction for human vascular smooth muscle cells. Atherosclerosis (1994) 110:53–61.
   PubMed Web of Science ®Google Scholar
• YANAGI H, SASAGURI Y, SUGAMA K, MORIMATSU M, NAGASE H: Production of tissue collagenase (matrix metalloproteinase 1) by human aortic smooth muscle cells in response to platelet-derived growth factor. Atherosclerosis (1992) 91:207–216.
   Web of Science ®Google Scholar
• PICKERING JG, FORD CM, TANG B, CHOW LH: Coordi-nated effects of fibroblast growth factor-2 on expres-sion of fibrillar collagens, matrix metalloproteinases and tissue inhibitors of matrix metalloproteinases by human vascular smooth muscle cells - Evidence for repressed collagen production and activated degrada-tive capacity. Arterioscler. Thromb. Vasc. Biol. (1997) 17(3)475–482.
   Google Scholar
• BOND M, FABUNMI RP, BAKER AH, NEWBY AC: Synergistic upregulation of metalloproteinase-9 by growth factors and inflammatory cytokines: an absolute requirement for transcription factor NF-kB. FEBS Lett. (1998) 435:29–34.
   PubMed Web of Science ®Google Scholar
• XU XP, MEISEL SR, ONG JM et al.: Oxidized low-density lipoprotein regulates matrix metalloproteinase-9 and its tissue inhibitor in human monocyte-derived macrophages. Circulation (1999) 99(8)993–998.
   Google Scholar
• •It is suggested in this paper that oxidised LDL stimulates MMP-9 in macrophages, whilst reducing TIMP-1 expression.
   Google Scholar
• AIKAWA M, RABKIN E, VOGLIC SJ et al.: Lipid lowering promotes accumulation of mature smooth muscle cells expressing smooth muscle myosin heavy chain isoforms in rabbit atheroma. Circ. Res. (1998) 93:1015–1026.
   Web of Science ®Google Scholar
• MACH F, SCHONBECK U, BONNEFOY J-Y, POBER JS, LIBBY P: Activation of monocyte/macrophage functions related to acute atheroma complication by ligation of CD40. Induction of collagenase, strome-lysin and tissue factor. Circulation (1997) 96:396–399.
   PubMed Web of Science ®Google Scholar
• MACH F, SCHONBECK U, SUKHOVA GK, ATKINSON E, LIBBY P: Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature (1998) 394 (6689):200–203.
   PubMed Web of Science ®Google Scholar
• ••This work clearly shows that CD40 ligation is involved inatherosclerotic plaque formation in mice lacking the LDL receptor.
   Google Scholar
• CARMELIET P, MOONS L, LUNEN R et al.: Urokinase-generated plasmin activates matrix metalloprote-inases during aneurysm formation. Nature Gen. (1997) 17:439–444.
   PubMed Web of Science ®Google Scholar
• SOUTHGATE KM, DAVIES M, BOOTH RFG, NEWBY AC: Involvement of extracellular-matrix-degrading metalloproteinases in rabbit aortic smooth-muscle cell proliferation. Biochem. j (1992) 288:93–99.
   PubMed Web of Science ®Google Scholar
• KENAGY RD, VERGEL S, MATTSSON E, BENDECK M, REIDY MA, CLOWES AW: The role of plasminogen, plasminogen activators and matrix metalloprote-inases in primate arterial smooth muscle cell migration. Arterioscler. Thromb. Vasc. Biol. (1996) 16(10:1373–1382.
   PubMed Web of Science ®Google Scholar
• ZEMPO N, KOYAMA N, KENAGY RD, LEA HJ, CLOWES AW: Regulation of vascular smooth muscle cell migration and proliferation in vitro and injured rat arteries by a synthetic matrix metalloproteinase inhibitor. Arterioscler. Thromb. Vasc. Biol. (1996) 16:28–33.
   PubMed Web of Science ®Google Scholar
• BENDECK MP, IRVIN C, REIDY MA: Inhibition of matrix metalloproteinase activity inhibits smooth muscle cell migration but not neointimal thickening after arterial injury. Circ. Res. (1996) 78:38–43.
   PubMed Web of Science ®Google Scholar
• PRESCOTT MF, SAWYER WK, VON LINDEN-REED J et al.: Effect of matrix metalloproteinase inhibition on progression of atherosclerosis and aneurysm in LDL receptor-deficient mice overexpressing MMP-3, MMP-12 and MMP-13 and on restenosis in rats after balloon injury. Ann. NY Acad. ScL (1999) 878:179–190.
   Google Scholar
• •The authors of this work suggest that MMP inhibitors may not be suitable for the treatment of atherosclerosis since treatment with a MMP inhibitor did not reduce lesion size or intimal thickening in rats.
   Google Scholar
• FOROUGH R, KOYAMA N, HASENSTAB D et al.: Overex-pression of tissue inhibitor of matrix metalloproteinase-1 inhibits vascular smooth muscle cell functions in vitro and in vivo. Circ. Res. (1996) 79:812–820.
   PubMed Web of Science ®Google Scholar
• •Demonstrated that increasing production of TIMP-1 by gene transfer in injured rat vessels reduces intimal thickening and suggests that this type of strategy may be useful in the treatment of atherosclerosis.
   Google Scholar
• DOLLERY CM, HUMPHRIES SE, MCCLELLAND A, LATCHMAN DS, MCEWAN JR: Expression of tissue inhibitor of matrix metalloproteinases 1 by use of an adenoviral vector inhibits smooth muscle cell migration and reduces neointimal hyperplasia in the rat model of vascular balloon injury. Circulation (1999) 99(24)3199–3205.
   Google Scholar
• •See reference 113 for annotation.
   Google Scholar
• FOROUGH R, LEA H, STARCHEF B et al.: Metalloprote-inase blockade by local overexpression of TIMP-1 increases elastin accumulation in rat carotid artery intima. Arterioscler. Thromb. Vasc. Biol. (1998) 18:803–807.
   PubMed Web of Science ®Google Scholar
• •See reference 113 for annotation.
   Google Scholar
• GEORGE SJ, BAKER AH, ANGELINI GD, NEWBY AC: Gene transfer of tissue inhibitor of metalloproteinase-2 inhibits metalloproteinase activity and neointima formation in human saphenous veins. Gene Therapy (1998) 5:1552–1560.
   PubMed Web of Science ®Google Scholar
• •Using human saphenous veins, this paper further supports the potential use of gene therapy using TIMPs, which may be useful for the treatment of atherosclerosis.
   Google Scholar
• GEORGE SJ, JOHNSON JL, ANGELINI GD, NEWBY AC, BAKER AH: Adenovirus-mediated gene transfer of the human TIMP-1 gene inhibits SMC migration and neointima formation in human saphenous vein. Hum. Gene Ther. (1998) 9:867–877.
   PubMed Web of Science ®Google Scholar
• •See reference 116 for annotation.
   Google Scholar
• CHENG L, MANTILE G, PAULY R et al.: Adenovirus-mediated gene transfer of the human tissue inhibitor of metalloproteinase-2 blocks vascular smooth muscle cell invasiveness in vitro and modulates neointimal development in vivo. Circulation (1998) 98(20)2195–2201.
   Google Scholar
• GEORGE SJ, LLOYD CT, ANGELINI GD, NEWBY AC, BAKER AH: Inhibition of late vein graft neointima formation in human and porcine modles by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. Circulation (2000) 101:296–304.
   PubMed Web of Science ®Google Scholar
• •This study suggests that TIMP-3 may be the best candidate for gene therapy treatment with TIMPs since it not only inhibits the activity of MMPs but also stimulates apoptosis.
   Google Scholar
• ROUIS M, ADAMY C, DUVERGER N et al.: Adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-1 reduces atherosclerotic lesions in apolipoprotein E-deficient mice. Circulation (1999) 100(5)533–540.
   Google Scholar
• ••This interesting study is the most direct demonstration todate, that gene therapy using TIMPs may be useful in the treatment of atheroscelerosis.
   Google Scholar
• BECKETT RP, DAVIDSON AH, DRUMMOND AH, HUXLEY P, WHITTAKER M: Recent advances in matrix metallo-proteinase inhibitor. Drug Dis. Today (1996) 1:16–26.
   Web of Science ®Google Scholar
• SANTOS 0, MCDERMOTT CD, DANIELS RG, APPELT K: Rodent pharmokinetic and anti-tumour efficacy studies with a series of synthetic inhibitors if matrix metalloproteinases. Clin. Exp. Metast. (1997) 15:499–508.
   PubMed Web of Science ®Google Scholar
• WOJTOWICZ-PRAGA S, TORRI J, JOHNSON M et al.: Phase I trial of Marmistat, a novel matrix metalloproteinase inhibitor, administered orally to patients with advanced lung cancer. J. Clin. Oncol. (1998) 16:2150–2156.
   PubMed Web of Science ®Google Scholar
• KOIVUNEN E, ARAP W, VALTANEN H et al.: Tumor targeting with a selective gelatinase inhibitor. Nature Biotech. (1999) 17:768–774.
   PubMed Web of Science ®Google Scholar
• ••This novel study highlights the potential of this type ofstrategy for inhibiting MMP activity.
   Google Scholar